Financial Performance - The company's revenue for Q1 2025 was ¥205,392,055, representing an increase of 18.07% compared to ¥173,961,209 in the same period last year[5] - Net profit attributable to shareholders was ¥31,271,385.80, a growth of 34.21% from ¥23,299,888.83 year-on-year[5] - The basic earnings per share (EPS) was ¥0.4108, showing a slight increase of 0.66% from ¥0.4081 in the same quarter last year[5] - The net profit for the current period is CNY 30,466,904.35, an increase of 30.5% compared to CNY 23,407,535.69 in the previous period[20] - Operating profit for the current period is CNY 34,198,502.35, up from CNY 26,548,829.39, reflecting a growth of 28.5%[20] - Total comprehensive income for the current period is CNY 30,012,749.11, compared to CNY 23,639,898.44 in the previous period, indicating an increase of 27.5%[21] Cash Flow - The net cash flow from operating activities reached ¥22,267,479.84, a significant increase of 271.83% compared to a negative cash flow of ¥12,958,838.82 in the previous year[5] - Cash flow from operating activities shows a net inflow of CNY 22,267,479.84, a significant recovery from a net outflow of CNY 12,958,838.82 in the previous period[21] - Cash flow from investing activities has a net inflow of CNY 33,490,700.58, down from CNY 192,655,455.86 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,293,814,316.32, reflecting a marginal increase of 0.26% from ¥2,287,843,452.73 at the end of the previous year[5] - Current assets totaled ¥1,914,102,023.90, slightly increasing from ¥1,909,332,075.29 at the beginning of the period[17] - Total liabilities decreased to ¥224,866,582.55 from ¥245,319,949.37, a reduction of 8.29%[18] - The total equity attributable to shareholders increased to ¥2,017,166,556.28 from ¥1,988,525,265.46, reflecting a growth of 1.44%[18] Expenses - The company reported a 36.96% increase in management expenses, totaling ¥21,672,318.02, primarily due to higher salaries for senior management and increased depreciation expenses[8] - Total operating costs amounted to ¥175,393,128.26, up from ¥147,343,738.56, reflecting a growth of 19.06%[19] - The operating cost specifically for goods sold was ¥100,652,125.63, compared to ¥84,306,283.80 in the prior period, indicating a rise of 19.43%[19] - The company incurred research and development expenses of CNY 12,802,274.95, an increase from CNY 10,710,324.27 in the previous period[20] - The company’s total tax expenses for the current period are CNY 3,934,457.38, compared to CNY 3,116,545.64 in the previous period, reflecting an increase of 26.2%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,036[10] - The largest shareholder, Tianjin Yuan Yi Enterprise Management Consulting Center, holds 17.91% of shares, totaling 13,630,000 shares[10] - Tianjin Wendi Enterprise Management Consulting Center holds 10.99% of shares, totaling 8,363,918 shares[10] - The foreign shareholder, HAL, holds 7.51% of shares, totaling 5,713,534 shares[10] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, indicating concentrated ownership[10] - There are no changes in the number of restricted shares for major shareholders during the reporting period[13] - The company has a lock-up period of 36 months for shares held by Tianjin Yuan Yi and Tianjin Wendi[13] Investment and Market Activity - Investment income rose by 85.84% to ¥2,151,218.98, attributed to increased returns from financial investments and joint ventures[8] - The company experienced an 82.62% decrease in net cash flow from investing activities, amounting to ¥33,490,700.58, mainly due to the purchase of liquidity products[8] - The company has not disclosed any new product developments or market expansion strategies during the call[12] - There are no indications of mergers or acquisitions discussed in the conference call[12] - The company has not provided specific future performance guidance or outlook in the reported documents[12]

Financial Performance - The company's operating revenue for 2024 reached ¥888,165,246.91, representing a 13.81% increase compared to ¥780,383,700.00 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥150,491,664.18, a 2.40% increase from ¥146,959,201.90 in 2023[20]. - The net cash flow from operating activities for 2024 was ¥150,098,058.16, up 7.14% from ¥140,091,445.87 in 2023[20]. - The total assets at the end of 2024 amounted to ¥2,287,843,452.73, an increase of 77.12% from ¥1,291,720,904.45 at the end of 2023[20]. - The net assets attributable to shareholders at the end of 2024 were ¥1,988,525,265.46, reflecting an 85.65% increase from ¥1,071,142,657.12 at the end of 2023[20]. - The basic earnings per share for 2024 decreased by 12.06% to ¥2.26 from ¥2.57 in 2023[20]. - The company reported a quarterly revenue of ¥247,035,522.11 in Q4 2024, contributing to a total annual revenue growth[22]. - The company achieved a revenue growth with overseas revenue share increasing from 44.5% in 2021 to 61.85% in 2024, with a compound annual growth rate of 138.7% for the overseas local operation team[54]. - The company reported a long-term effective classification for its dental zirconia ceramic materials, indicating a focus on high-quality dental restorations[86]. Dividends and Capital Reserves - The company plans to distribute a cash dividend of 6.5 yuan per 10 shares (including tax) to all shareholders, based on a total of 76,117,527 shares[3]. - The company will also increase capital reserves by converting 4 shares for every 10 shares held by shareholders[3]. Governance and Management - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons and accounting heads[3]. - All board members attended the meeting to review the annual report, ensuring collective responsibility for its content[3]. - The company has a comprehensive governance structure in place, as outlined in the corporate governance section of the report[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in forward-looking statements[3]. - The company has established a performance evaluation and incentive mechanism, linking management compensation to operational performance metrics[155]. - The board of directors consists of 9 members, including 3 independent directors with expertise in accounting, law, and industry background, complying with legal requirements[151]. - The company maintains a fully independent financial accounting system, with separate bank accounts and no shared accounts with the controlling shareholder[163]. - The company has a complete and independent business system, including R&D, production, and sales capabilities, without reliance on the controlling shareholder[166]. - The company has established an audit committee under the board to oversee internal and external audits, ensuring compliance and effectiveness[158]. Research and Development - R&D investment reached 47.36 million yuan, representing an 18.21% year-on-year increase, with a total of 153 valid patents held by the company as of December 31, 2024[58]. - R&D investment amounted to ¥47,361,902.27 in 2024, representing 5.33% of operating revenue[79]. - The company is developing a new dental zirconia material that can be sintered in 30 to 60 minutes, enhancing production efficiency[77]. - The company is working on a digital cloud system for dental management to improve customer service efficiency and satisfaction[77]. - The company is focusing on innovative materials, such as zirconia and glass ceramics, for dental restorations, which are currently in various stages of registration[81]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[28]. - The company has actively expanded into emerging markets such as Southeast Asia, the Middle East, and Australia, further increasing market share[54]. - The company aims to reduce the bonding failure rate of zirconia veneers through a new surface treatment agent[78]. - The company is exploring acquisition opportunities, targeting firms with complementary technologies valued at approximately $100 million[177]. - The company plans to pursue external investments and acquisitions to enhance its industry position and integrate cutting-edge technologies globally[126]. Product Development and Innovation - The company has developed a product ecosystem covering dental restoration, implants, orthodontics, and prevention, enhancing customer satisfaction and loyalty[56]. - The company is committed to continuous technological innovation and product upgrades to maintain its leading position in the industry amidst competitive pressures[37]. - The company has introduced a new line of porcelain powders suitable for customized denture crowns, targeting adults over 18 years old[82]. - The company has registered new products, including dental films and CAD/CAM materials, with registration valid until 2029[83]. - The company is focusing on expanding its product offerings in the dental sector, particularly in the area of ceramic restorations[83]. Financial Management and Cash Flow - Operating cash inflow for 2024 reached ¥930,987,237.26, a year-on-year increase of 10.48% compared to ¥842,665,047.90 in 2023[95]. - Financing cash inflow for 2024 was ¥794,007,249.81, marking a significant increase due to funds raised from the IPO[95]. - The net increase in cash and cash equivalents for 2024 was ¥132,304,919.96, down 57.04% from ¥307,965,654.67 in 2023[95]. - The company has confirmed that all projects are on schedule and have not encountered significant changes in feasibility[117]. Shareholder Engagement and Communication - The company conducted multiple investor communication activities in July 2024, including phone meetings and on-site research with various institutional investors[143][144][145]. - The company ensures equal treatment of all shareholders and upholds the rights of minority shareholders during shareholder meetings[149]. - The company continues to engage with shareholders through regular meetings and transparent communication[167]. Employee and Talent Management - The total number of employees at the end of the reporting period is 959, with 782 from the parent company and 177 from major subsidiaries[195]. - The company plans to strengthen its talent pool by focusing on recruiting high-end marketing and international management talents[134]. - The educational background of employees shows 127 with master's degrees or above, 439 with bachelor's degrees, and 393 with associate degrees or below[196]. Compliance and Risk Management - The company has obtained necessary certifications for its products in major international markets, including FDA and CE certifications, to mitigate compliance risks[138]. - The company will actively monitor international market policies to address potential tariff impacts on exports to the U.S.[141]. - The company has not reported any significant changes in its operational strategy during the reporting period[170].

2、召开方式：线上会议 3、交流内容：公司将针对 2024 年年度经营成果、财务指标等与投资者进 行交流，并对投资者普遍关注的问题进行回答。 4、出席人员：董事长、总经理李洪文先生；董事会秘书、副总经理郜雨女 士；财务总监孔祥乾先生；独立董事贾国军先生；董事王雪松女士。（具体以 当天实际参会人员为准） 证券代码： 301580 证券简称：爱迪特 公告编号： 2025-001 爱迪特（秦皇岛）科技股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）将于 2025 年 4 月 29日在巨潮资讯网（www.cninfo.com.cn）披露《2024年年度报告》。为加强 与投资者交流，使投资者更全面、深入地了解公司经营情况，公司将于 2025 年 4 月 29 日（星期二）召开 2024 年度业绩说明会。 一、业绩说明会安排 1、召开时间：2025 年 4 月 29 日（星期二）15:00-16:00 问题征集二维码 三、咨询方式 咨询机构：爱迪特（秦皇岛）科技股份 ...

| | □特定对象调研 | □分析师会议 | | --- | --- | --- | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | 团现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称 | 招商证券 张语馨 国泰基金 任一林 | | | 及人员姓名 | | | | 时间 | 2025年1月13日 | | | 地点 | 公司会议室 | | | 上市公司接待 | 董事会秘书 部雨 | | | 人员姓名 | 投资者问答主要内容: | | | | 1. 公司如何看待国内的价格竞争? | | | 答: | | | | | 在前些年国内确实出现过低价竞争的情况,但从结果来看 | | | 投资者关系活动 主要内容介绍 | 优质产品是能够被客户认知和认可的。伴随着中国口腔行业发 | | | | 展成熟度越来越高,以及公司通过长期研发投入获得了一定市 | | | | 场和客户的认可与信赖,给客户提供技术领先、质量稳定、价 | | | | 格适中的产品成为公司核心竞争力。 | | | | 2. 目前销售氧化链结构如何变化? | ...

证券代码：301580 证券简称：爱迪特 | --- | --- | |-------|-------------------------------------------------------------| | | | | | 2. 公司存货周转水平上升的原因是什么？ 答： | | | 存货增加系阶段性的波动导致。首先，公司今年更新 ERP | | | 系统，上线 SAP 系统对公司海内外分支做高效管理，在此期间 | | | 增加了安全库存储备以保障系统切换期间订单的及时交付；第 | | | 二，针对个别区域的发展需求，公司对海外仓适当增加了一定 | | | 存货。 | | | 3. 公司设立美国、德国子公司负责欧美核心市场的运营，但日、 | | | 韩两国相比欧美市场规模较小却设立子公司基于何种考虑？ | | | 答： | | | 日、韩两国口腔市场发展较为成熟，在国际上认可度较高， | | | 公司在日韩设立子公司进行本土化运营旨在提升公司产品竞 | | | | | | 争力和品牌知名度。 | | | 4. 公司沃兰种植体销售情况如何？ | | | 答： | | | 公司收购沃兰后渠道整合及市场拓展 ...

证券代码：301580 证券简称：爱迪特 公告编号：2024-028 爱迪特（秦皇岛）科技股份有限公司 首次公开发行网下配售限售股上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次上市流通的限售股为爱迪特（秦皇岛）科技股份有限公司（以下简称"爱 迪特"或"公司"）首次公开发行网下配售限售股。 本次上市流通的限售股份数量为981,755股，解除限售股东数量为6,012户， 占公司总股本的 1.29%，限售期为自公司股票上市之日起 6 个月。 二、申请解除股份限售股东履行承诺情况 根据公司《首次公开发行股票并在创业板上市之上市公告书》，本次申请解 除股份限售的网下发行投资者均受限于如下限售安排： "网下发行部分采用比例限售方式，网下投资者应当承诺其获配股票数量的 10%（向上取整计算）限售期限为自发行人首次公开发行并上市之日起 6 个月。 即每个配售对象获配的股票中，90%的股份无限售期，自本次发行股票在深圳证 券交易所上市交易之日起即可流通；10%的股份限售期为 6 个月，限售期自本次 发行股票在深圳证券交易所上市交易之日起开始 ...

中信建投证券股份有限公司 关于爱迪特（秦皇岛）科技股份有限公司 首次公开发行网下配售限售股份上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"） 作为爱迪特（秦皇岛）科技股份有限公司（以下简称"爱迪特"或"公司"） 首次公开发行股票并在创业板上市的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等有关规定，对爱迪特首次公开发行网 下配售限售股份上市流通的事项进行了核查，具体情况如下： 一、首次公开发行网下配售股份概况 经中国证券监督管理委员会《关于同意爱迪特（秦皇岛）科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2023]2615 号）同意，公司首次 公开发行新股 19,029,382 股，于 2024 年 6 月 26 日在深圳证券交易所上市交易。 首次公开发行前公司总股本为 57,088,145 股，首次公开发行股票完成后公 司总股本为 76,117,527 股，其中无流通限制或限售安排股票 ...

参会人员：全体董事、监事、高级管理人员等。 二、培训的主要内容 本次培训内容主要包括： 1、上市公司信息披露、规范运作相关业务规则修订情况及重点关注事项解读。 中信建投证券股份有限公司 关于爱迪特（秦皇岛）科技股份有限公司 2024年度持续督导培训报告 中信建投证券股份有限公司（以下简称"保荐人"或"中信建投证券"）作 为爱迪特（秦皇岛）科技股份有限公司（简称"爱迪特"或"公司"）首次公开 发行股票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第2号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引 第13号——保荐业务》等有关规定，于2024年12月12日对爱迪特相关人员进行了 培训，培训情况如下： 一、培训的时间和地点及参会人员 时间： 2024年12月12日 地点：爱迪特会议室及线上会议 3、分享近期市场政策，结合近期市场案例，通过案例分析以及违规案例启示 等方式传达最新的监管动态。 三、培训的完成情况及效果 本次持续督导培训的工作过程中，全体参与培训人员均进行了认真深入学习， 对于上市公司的规范运营 ...

证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛）科技股份有限公司投资者关系活动记录表 编号：2024-013 | --- | --- | --- | |-----------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | ☑ 分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 长城基金-谭小兵；平安养老 | - 邵瑾良；国泰基金-戴计辉；浦银 | | | 安盛 - | 徐博；德邦-曾叙衡；招银理财-熊超逸；上海东方证券- | | 参与单位名称 | | 刘中群、邹秉昂；上海肇万-李大瑞；广发-王瑞冬；银河-方伟； | | 及 ...

爱迪特（秦皇岛） 科技股份有限公司投资者关系活动记录表 证券代码：301580 证券简称：爱迪特 编号：2024-012 | --- | --- | --- | --- | |-----------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------------------------|------------------| | | □特定对象调研 | ☑ 分析师会议 | | | | □媒体采访 □业绩说明会 | | | | 投资者关系 活动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | | 华泰资产、华夏基金、招商基金、奥博资本、创金合信、前海 人寿、安信基金、理成资产、睿亿投资、招商资管香港、万和 | | | 时间 2024 | 年 ...